Proxorphan

Proxorphan

Proxorphan
Systematic (IUPAC) name
17-(cyclopropylmethyl)-6-oxamorphinan-3-ol
or
(1S,9R,10R)-17-(cyclopropylmethyl)-13-oxa-17-azatetracyclo[7.5.3.0~1,10~.0~2,7~]heptadeca-2,4,6-trien-4-ol
Clinical data
Legal status
?
Identifiers
CAS number
ATC code None
ChemSpider
UNII  YesY
Chemical data
Formula C19H25NO2 
Mol. mass 299.41 g/mol

Proxorphan is an opioid analgesic and antitussive drug of the morphinan family that was never marketed.[1] It acts as a κ-opioid receptor partial agonist and to a lesser extent as a μ-opioid receptor partial agonist.[2][3][4][5]

See also

References

  1. ^ David J. Triggle (1997). Dictionary of pharmacological agents. London: Chapman & Hall.  
  2. ^ Leander JD (October 1983). "Further study of kappa opioids on increased urination". The Journal of Pharmacology and Experimental Therapeutics 227 (1): 35–41.  
  3. ^ Hayes AG, Birch PJ (August 1988). "Reversal by beta-funaltrexamine and 16-methyl cyprenorphine of the antinociceptive effects of opioid agonists in the mouse and guinea-pig". Neuropharmacology 27 (8): 813–6.  
  4. ^ Picker MJ, Dykstra LA (May 1989). "Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists". The Journal of Pharmacology and Experimental Therapeutics 249 (2): 557–66.  
  5. ^ Picker MJ, Craft RM, Negus SS, et al. (November 1992). "Intermediate efficacy mu opioids: examination of their morphine-like stimulus effects and response rate-decreasing effects in morphine-tolerant rats". The Journal of Pharmacology and Experimental Therapeutics 263 (2): 668–81.